Key points from article :
Rejuvenate Biomed completed a EUR 3.2 million Series A round.
To advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia.
The financing included lead investor Vesalius Biocapital III and private non-disclosed investors, as well as existing investors.
RJx-01 is a novel, safe, orally administered, small molecule combination product being developed for sarcopenia.
Product was derived from an extensive in silico systems biology program.
Mapped existing drugs with longevity pathways to create innovative, synergistic and highly effective combinations.
Demonstrated strong preclinical evidence in multiple models.
With human safety data on hand for the individual compounds, the company plans to move into Phase Ib/IIb clinic trials later this year.
“...deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes," - Ann Beliën, Founder and CEO of Rejuvenate.
